Login / Signup

Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.

Martin JäderstenKsenia BoriskinaCarolin LindholmSimone WeströmLucia CavelierEva Hellström-LindbergStephan MielkeMagnus Tobiasson
Published in: Leukemia & lymphoma (2021)
Keyphrases
  • stem cell transplantation
  • acute myeloid leukemia
  • high dose
  • chronic lymphocytic leukemia
  • low dose